To investigate whether combined therapy would be more efficacious than 177Lu-EB-RGD or anti-PD-L1 mAb alone, a study was performed with five groups (A-E), each including 9-10 MC38 tumor-bearing mice. This evidence concerns the gene CD274 and neoplasm.